

Multi-omic network analysis identifies dysregulated neurobiological pathways in opioid addiction

Kyle A. Sullivan¹, David Kainer¹, Matthew Lane², Mikaela Cashman^{1,3}, J. Izaak Miller¹, Michael R. Garvin¹, Alice Townsend², Bryan C. Quach⁴, Caryn Willis⁴, Peter Kruse², Nathan C. Gaddis⁴, Ravi Mathur⁴, Olivia Corradin⁵, Brion S. Maher⁶, Peter C. Scacheri⁷, Sandra Sanchez-Roige^{8,9}, Abraham A. Palmer^{8,10}, Vanessa Troiani¹¹, Elissa J. Chesler¹², Rachel L. Kember^{13,14}, Henry R. Kranzler^{13,14}, Amy C. Justice^{15,16,17}, Ke Xu^{15,18}, Bradley E. Aouizerat¹⁹, VA Million Veteran Program, Dana B. Hancock^{4*}, Eric O. Johnson^{4,20*}, and Daniel A. Jacobson^{1*}

¹Biosciences Division, Oak Ridge National Laboratory, Oak Ridge, TN

²The Bredesen Center for Interdisciplinary Research and Graduate Education, University of Tennessee-Knoxville, Knoxville, TN

³Environmental Genomics and Systems Biology Division, Lawrence Berkeley National Laboratory Berkeley, CA

⁴RTI International, Research Triangle Park, NC

⁵Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology, Cambridge, MA

⁶Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

⁷Department of Genetics and Genome Sciences, Case Western Reserve University, Cleveland, OH

⁸Department of Psychiatry, University of California San Diego, La Jolla, CA

⁹Division of Genetic Medicine, Vanderbilt University Medical Center, Nashville, TN

¹⁰Institute for Genomic Medicine, University of California San Diego, La Jolla, CA

¹¹Geisinger College of Health Sciences, Scranton, PA

¹²The Jackson Laboratory, Bar Harbor, ME

¹³Mental Illness Research, Education and Clinical Center, Crescenz Veterans Affairs Medical Center, Philadelphia, PA

¹⁴Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA

¹⁵Veterans Affairs Connecticut Healthcare System, West Haven, CT

¹⁶Department of Internal Medicine, Yale University School of Medicine, New Haven, CT

¹⁷Department of Health Policy and Management, Yale School of Public Health, New Haven, CT

¹⁸Department of Psychiatry, Yale School of Medicine, New Haven, CT

¹⁹Bluestone Center for Clinical Research, College of Dentistry, New York University, New York, NY

²⁰Fellow Program, RTI International, Research Triangle Park, NC

*Correspondence: jacobsonda@ornl.gov, ejohnson@rti.org, dhancock@rti.org

This manuscript has been authored by UT-Battelle, LLC under Contract No. DE-AC05-00OR22725 with the U.S. Department of Energy. The United States Government retains and the publisher, by accepting the article for publication, acknowledges that the United States Government retains a non-exclusive, paid-up, irrevocable, world-wide license to publish or reproduce the published form of this manuscript, or allow others to do so, for United States Government purposes. The Department of Energy will provide public access to these results of federally sponsored research in accordance with the DOE Public Access Plan (<http://energy.gov/downloads/doe-public-access-plan>).

1 **Abstract**

2 Opioid addiction constitutes a public health crisis in the United States and opioids cause
3 the most drug overdose deaths in Americans. Yet, opioid addiction treatments have limited
4 efficacy. To help address this problem, we used network-based machine learning techniques to
5 integrate results from genome-wide association studies (GWAS) of opioid use disorder and
6 problematic prescription opioid misuse with transcriptomic, proteomic, and epigenetic data from
7 the dorsolateral prefrontal cortex (dlPFC) in opioid overdose victims. We identified 211 highly
8 interrelated genes identified by GWAS or dysregulation in the dlPFC of individuals with opioid
9 overdose victims that implicated the Akt, BDNF, and ERK pathways, identifying 414 drugs
10 targeting 48 of these opioid addiction-associated genes. This included drugs used to treat other
11 substance use disorders and antidepressant drugs. Our synthesis of multi-omics using a systems
12 biology approach revealed key gene targets that could contribute to drug repurposing, genetics-
13 informed addiction treatment, and future discovery.

14 **Introduction**

15
16 Worldwide, over 60 million people misuse opioid drugs resulting in an estimated 12.9
17 million healthy years of life lost (disability-adjusted life years)¹. These drugs include both opioids
18 prescribed for pain relief (*e.g.*, hydrocodone, oxycodone) and illicit opioids (*e.g.*, heroin, fentanyl).
19 In the United States, over 9 million people in the housed population (which excludes homeless and
20 institutionalized individuals) aged 12 and older were estimated to misuse opioids in 2020², and
21 over 80,000 people died of an opioid-related overdose in 2021 – continuing a decades long
22 epidemic of opioid misuse and overdose deaths^{3,4}. Yet only 1.27 million people in the United States
23 receive medication-assisted treatment with one of the three medications approved to treat opioid
24 use disorder (OUD)⁵: methadone (opioid agonist), buprenorphine (opioid agonist/antagonist), or
25 naltrexone (opioid antagonist). Substance use disorders are widely accepted to involve genetic and
26 experiential influences on brain circuits related to motivated behavior. Thus, there is a great need
27 for a better understanding of the neurobiology of opioid addiction and the identification of novel
28 targets for drug development.

29 Several recent genome-wide association studies (GWAS)^{6–10} have identified genetic
30 variants and genes associated with increased risk of opioid addiction phenotypes. Other studies
31 have identified gene dysregulation in postmortem human brains associated with opioid overdose
32 deaths^{11–15}. Up to 18 genome-wide significant loci have been reported across the most recent
33 GWASs for OUD or prescription opioid misuse, with replicated associations being observed for
34 *OPRM1*^{7–10}, *FURIN*^{7–9}, the *SCAI/PPP6C/RABEK* cluster^{7–9}, and *PTPRF*^{6,9}. In parallel, four
35 RNA-seq studies identified hundreds of potentially differentially expressed genes in human
36 postmortem dorsolateral prefrontal cortex (dlPFC), which were enriched for a variety of biological
37 functions (*e.g.*, extracellular matrix, angiogenic cytokines, and MAPK signaling). These studies

38 did not include replication, but we found that 11 genes replicate across these cohorts for the dlPFC
39 (Bonferroni corrected $p < 0.05$), and a meta-analysis¹⁶ of these cohorts identified up to 335
40 dysregulated genes in the dlPFC (Benjamini-Hochberg FDR p-value < 0.05).

41 Although these recent findings provide important clues to the biology underlying opioid
42 addiction, these genes do not function in isolation. Additional insights may be gained through a
43 systems biology approach that identifies affected functional networks from disease-associated
44 genes¹⁷. Here, we used results from existing studies to identify 404 opioid addiction-related genes
45 from which we removed potential false positives with the recently developed Gene set Refinement
46 through Interacting Networks (GRIN¹⁷) software. GRIN enabled us to identify a tightly integrated
47 set of 211 genes that mapped to multiple neurobiological pathways. Fifty of the 211 genes
48 implicated in opioid addiction signaling or other substance use disorders were tightly
49 interconnected using cross validation and a concise shortest-paths network between pairs of genes.
50 We created a conceptual model of the network mapped to BDNF and MAPK signaling pathways
51 and synaptic signaling processes, among others, showing widespread downregulation of these
52 genes in opioid addiction. Moreover, multiple genes appear to be promising targets for novel drug
53 repurposing for treating OUD based on their role as gene targets for drugs used to treat other
54 substance use disorders. Our results demonstrate the utility of integrating multiple omics in
55 systems biology approaches that leverage machine learning techniques, discovering novel
56 biological relationships that underlie opioid addiction.

57 **Results**

58 *Meta-analysis of opioid addiction omics data sets combined with network biology identifies 211*
59 *highly interrelated genes.*

60 We first identified opioid addiction-associated genes from multiple omics data sets using
61 the postmortem dlPFC and GWAS SNP-nearest gene assignment (**Figure 1**). Using consistent
62 significance thresholds within each omics data set across studies (Online Methods), we identified
63 404 unique opioid addiction genes from the following omics data types: 256 genes associated with
64 H3K27ac ChIP-seq peaks¹¹, 13 DNA methylation-associated genes¹⁵, 33 GWAS-associated
65 genes⁶⁻¹⁰, 3 protein-coding genes associated with differentially abundant proteins from LC/MS
66 proteomics¹², and 104 differentially expressed genes from RNA-seq¹¹⁻¹⁴ (**Supplementary Tables**
67 **1-7**).

68 Of the 404 opioid addiction-related genes, we sought to identify those that are highly
69 interconnected in biological networks using multiple lines of experimental evidence from data
70 independent of the opioid omics data sets. Using GRIN¹⁷, we removed potential false positive
71 genes based on network connectivity within a multiplex network consisting of 10 layers of
72 biological evidence. GRIN uses the algorithm Random Walk with Restart (RWR) to identify
73 tightly interconnected genes and removes those that do not depart from the gene ranks of a null
74 distribution. GRIN identified 211 highly interrelated opioid addiction genes across omics data
75 types (**Figure 2A, Supplementary Tables 8-9**).

76 Before GRIN filtering, the 404 unfiltered genes were significantly enriched for 103 Gene
77 Ontology (GO¹⁸) Biological Process terms. The 211 genes that remained after GRIN filtering were
78 enriched for 293 terms, including 96 of the same enriched biological processes as were in the
79 unfiltered gene set prior to the application of GRIN (**Figure 2B, Supplementary Tables 10-11**).
80 In contrast, the 193 genes removed by GRIN were not significantly enriched for any GO Biological
81 Process terms, clearly differentiating them from the 211 retained genes. Thus, the subset of 211

82 genes retained by GRIN were highly biologically interrelated based on interconnectivity within
83 the biological multiplex network and better mapping to known biological processes.

84

85 *A subset of multi-omic genes previously implicated in opioid signaling and substance use disorders*
86 *are highly interconnected in biological networks.*

87 Of the 211 genes retained by GRIN, we focused on a subset of 50 unique, high-confidence
88 genes (**Supplementary Table 12**) that were either implicated across 2 or more studies or
89 previously implicated in opioid signaling or in other substance use disorders (Online Methods).
90 Gene set enrichment analyses indicated that, among other functions, these high confidence genes
91 were enriched for the BDNF and MAPK signaling pathways and synaptic signaling processes
92 (**Supplementary Table 13**).

93 Using shortest paths network traversal to identify the fewest connections between each pair
94 of the 50 high-confidence opioid addiction genes, we found that 43 were directly connected to at
95 least one other gene in the set (**Figure 3A, Supplementary Table 14**). Moreover, the other 7 high
96 confidence genes were only two connections away from at least one of the other 50 high confidence
97 genes (**Figure 3A, Supplementary Table 14**). Only 127 additional network-connecting genes (not
98 high-confidence opioid addiction genes) were necessary to link pairs of genes that could be
99 connected as direct neighbors or by a shared neighboring gene. Furthermore, 3 of the 127 network-
100 connecting genes (*SERPINB1*, *SORCSI*, and *SORLI*) were members of the original 211 GRIN-
101 retained gene set (**Figure 3A, Supplementary Table 15**).

102 Next, we explored the interconnectivity of the 50 high-confidence opioid addiction genes
103 using RWR. We employed a cross-validation approach in which a subset of the opioid addiction
104 genes were used as starting points to explore the biological networks with RWR, and the remaining

105 genes were ranked against the rest of the genes in the biological network based on how often the
106 gene was visited by RWR. Using this cross-validation approach, we observed a high area under
107 receiver-operator characteristic curve (AUROC) value (AUROC = 0.94; **Figure 3B**). The high
108 AUROC value indicated that, during cross validation, genes that were used to explore the networks
109 frequently visited the genes that were left out of the gene set. Combined with our small shortest
110 paths network, these results confirmed that these 50 genes were highly interconnected in our
111 biological multiplex network.

112

113 *Conceptual model of biological pathways underlying opioid addiction multi-omic genes.*

114 After integrating the 211 multi-omic opioid addiction genes using our network approaches,
115 we identified multiple pathways unifying these genes. From this investigation, we developed a
116 conceptual model consisting of 45 opioid addiction genes and 26 other genes, proteins, or
117 molecules in associated pathways (**Figure 4**). Multiple genes in the BDNF pathway were
118 implicated, including *BDNF*, whose expression was downregulated and its receptor *NTRK2*
119 (*TrkB*), which exhibited decreased H3K27ac ChIP-seq peaks in opioid samples (**Figure 4**). A
120 number of genes were also implicated downstream of the BDNF pathway, including *RASGRF1*,
121 *PIK3R1* and *GSK3B* in the PI3K/Akt pathway. The ERK MAPK pathway was also strongly
122 implicated, as the μ -opioid receptor (*OPRM1*), GABA_B receptor (*GABBR2*), and *PDE4B* were
123 implicated upstream of ERK along with multiple ERK phosphatases (*DUSP2*, *DUSP4*, *DUSP6*,
124 *DUSP10*, *PPP6C*). Downstream of the ERK and Akt pathways, CREB (*CREB5*) and a number of
125 its target genes were also implicated in opioid addiction, including several immediate early genes
126 (*ARC*, *EGR1*, *EGR2*, *EGR4*, *FOS*, *MYC*, *NPAS4*) and genes involved in synaptic plasticity (*BDNF*,

127 *NTNI*)¹⁹. Additionally, the transcription factor *RORA* was predicted to activate the transcription of
128 the multi-omic opioid addiction genes: astrotactin-2 (*ASTN2*) and galectin-3 (*LGALS3*)²⁰.

129 In addition to the BDNF, ERK, and Akt signaling pathways, multiple ion channel subunits
130 and cell adhesion molecules that may influence neurotransmission were identified by multi-omic
131 integration. Filamin A (*FLNA*) binds OPRM1²¹, FURIN²², and the GRIK3 subunit of the kainate
132 glutamatergic receptor²³ (**Figure 4**). Moreover, the astrocytic glutamate transporter EAAT2 gene
133 (*SLCIA2*) was implicated by hypoacetylated ChIP-seq. Multiple ionotropic GABA receptor
134 subunit genes (*GABRE*, *GABRG3*), a voltage-gated calcium channel subunit gene (*CACNB2*), and
135 multiple ATP or Ca²⁺-activated K⁺ channel subunit genes (*ABCC8*, *KCNMA1*, *KCNN1*) were
136 identified by ChIP-seq, GWAS, or RNA-seq. Genes encoding cell adhesion molecules (*NCAMI*
137 ²⁴, *NRXN3*²⁵) that can modulate synaptic connectivity were also implicated in our multi-omic
138 opioid addiction gene set, and microglial inflammation was implicated by the galectin-3 gene
139 (*LGALS3*²⁶). Notably, most genes exhibited decreased gene expression, hypoacetylated H3K27ac
140 peaks, or increased DNA methylation, except for increased *GABRE* and *MYC* gene expression and
141 increased protein abundance of *LGALS3*.

142

143 *Putative pharmacological target genes in opioid addiction.*

144 After identifying biological pathways and highly interrelated genes by integrating the
145 multi-omic opioid addiction data sets, we identified genes whose protein products are candidates
146 for pharmacological manipulation and potential drug repurposing. We constructed a network of
147 48 druggable opioid addiction genes and 414 approved or experimental drugs known to target the
148 products of these genes (**Figure 5, Supplementary Table 16**). Currently approved treatments for
149 opioid use disorder (OUD) or overdose that target the mu-opioid receptor (encoded by *OPRM1*)

150 are included in the network (buprenorphine, methadone, nalmefene, naloxone, and naltrexone).
151 Naltrexone is also approved for treating alcohol use disorder (AUD)²⁷, and other approved or
152 investigational AUD treatments²⁷ were also present in the network, such as acamprosate²⁷ (*GABRE*
153 and *GABRG3*), baclofen²⁷ (*GABBR2*), ibudilast²⁸ (*PDE4B*), and topiramate^{27,29} (*CACNB2*, *GRIK3*,
154 and *SCN8A*; **Figure 5, Supplementary Table 16**).

155 In addition to drugs approved for treating substance use disorders, multiple drugs in the
156 network targeting opioid addiction multi-omic genes are currently approved for psychiatric
157 treatment or are known to have psychiatric effects. This includes the drug spironolactone (targeting
158 *CACNB2* and *PGR*), which has recently been investigated for treating AUD³⁰, and multiple
159 approved antidepressants^{31,32} such as amitriptyline (*ADRAID*, *NTRK2*, *OPRM1*), amoxapine
160 (*ADRAID*, *GABRE*, *GABRG3*), and esketamine (*BDNF*, *NTRK2*). The network also includes
161 known drugs of abuse (e.g., opioids, ethanol, promethazine) and widely prescribed drugs with
162 potential for misuse, including antipsychotics (e.g., aripiprazole^{33,34} (*OPRM1*), dosulepin³⁵
163 (*ADRAID*), olanzapine³³ (*GABRG3*), pipamperone³³ (*ADRAID*), quetiapine^{33,36} (*ADRAID*) and
164 benzodiazepines (e.g., alprazolam³⁷, lorazepam³⁸, temazepam³⁸ that all target *GABRE* and
165 *GABRG3*). A number of opioids are also present in the drug-gene target network based on their
166 characterized effects on *OPRM1*.

167 Furthermore, multiple ionotropic and metabotropic ion channel and receptor subunits
168 (*ADRAID*, *CACNB2*, *GABBR2*, *GABRE*, *GABRG2*, *GRIK3*, *KCNE4*, *KCNMA1*, *KCNS3*, *NTRK2*,
169 *OPRM1*, *SCN8A*) that were identified by multi-omic integration are known targets of approved
170 drugs. Many drugs (“Other Drugs”, **Figure 5**) targeted 2 or more of the multi-omic opioid
171 addiction genes that have not been investigated for psychiatric effects. For example, 9 genes
172 (*DAPK1*, *GSK3B*, *HIPK3*, *MARK1*, *NTRK2*, *PAK3*, *PLK4*, *STK17B*, and *STK24*) were targeted by

173 fostamatinib, indicating its potential to affect many opioid addiction genes simultaneously.
174 Furthermore, we identified antagonists and agonists for most of the gene targets present in the
175 conceptual model in **Figure 4** that were druggable, except for *FURIN* (only inhibitors), *GABBR2*
176 (only agonists), *LGALS3* (unknown action), *SLCIA2* (substrate or inhibitors), and *SST* (only
177 substrates). Thus, many of the genes in the biological pathways identified by our multi-omic
178 integration are druggable targets and are novel candidates for drug repurposing studies.

179 **Discussion**

180 In the present study, we integrated multi-omic datasets using a systems biology approach
181 to identify biological pathways and drug targets underlying opioid addiction. Importantly, by
182 integrating genome-wide association studies and omics derived from the dlPFC of individuals who
183 died from an opioid overdose, we identified distinct biological pathways implicated in this brain
184 region, which is associated with opioid craving³⁹⁻⁴¹, such as the Akt and BDNF signaling
185 pathways, which were not identified in the original contributing studies. Drug-gene target network
186 integration identified candidate drugs targeting gene products implicated in opioid addiction
187 omics, as well as putative gene targets for experimental follow up. These efforts may inform the
188 development of therapeutic interventions for opioid addiction.

189 After identifying GWAS and omics-derived genes using consistent thresholds across
190 opioid addiction studies, we used GRIN¹⁷ as a means of integrating these multi-omic data by
191 identifying the most interrelated genes based on biological network connectivity. We used our
192 previous validated multiplex network containing a dlPFC-derived predictive expression network
193 in order to remove false positive genes from our gene set. Moreover, the dlPFC-specific network
194 layers were congruent with the tissue of all transcriptomic and epigenetic data sets examined.
195 Importantly, the 211 genes retained by GRIN were enriched for more GO Biological Processes

196 than the 404 genes not filtered by GRIN. From the 211 genes, we identified a subset of 50 that
197 were either previously implicated in the risk for substance use disorders, in opioid receptor
198 signaling, or by multiple opioid addiction omics. Based on the high AUROC value from our
199 random walk with restart cross-validation approach and the fact that only 127 genes were needed
200 to connect opioid addiction genes in a shortest paths network, we concluded that these 50 genes
201 were highly interconnected in our multiplex network and therefore part of the same biological
202 pathways. Notably, while some of these genes have previously been implicated in rodent models
203 of opioid addiction (*e.g.*, *FOS*⁴²⁻⁴⁴, *MYC*^{45,46}) or opioid receptor signaling (*NTN1*⁴⁷, *RTP4*^{48,49}),
204 many of the other genes are not well-characterized in relation to opioid addiction or from human
205 postmortem brain tissue.

206 Gene set enrichment analysis revealed a strong enrichment for the BDNF, ERK, and
207 Akt/PI3K pathways from our opioid addiction genes. Notably, the study describing the LC/MS
208 proteomics data set and two RNA-seq data sets previously implicated the p38 and ERK MAPK
209 pathways^{11,12}. Here, we confirm this finding and expand the implication of the ERK MAPK
210 pathway beyond the genes identified in prior studies. Animal models have shown increased ERK
211 phosphorylation in the hippocampus⁵⁰ and of the ERK scaffold protein PEA-15⁵¹. Decreased
212 BDNF and associated epigenetic alterations have also been observed in the ventral tegmental area
213 of postmortem tissue from human heroin addicts⁵². Moreover, the Akt/PI3K pathway has been
214 implicated in differential gene expression from whole blood of subjects diagnosed with opioid use
215 disorder⁵³. However, to our knowledge this is the first study from the dlPFC in which multiple
216 genes in the BDNF (*BDNF*, *NTRK2*) and Akt pathways (*GSK3B*, *PIK3R1*, *RASGRF1*) were
217 implicated by opioid-induced transcriptomic and epigenetic alterations.

218 We also note that many of the 45 genes in our dlPFC opioid addiction conceptual model
219 affect synaptic plasticity or neuronal signaling, and were largely associated with H3K27
220 hypoacetylation and/or decreased gene expression. Both excitatory receptor subunits (*CACNB2*,
221 *GRIK3*) and inhibitory receptor subunits (*ABCC8*, *GABBR2*, *GABRE*, *GABRG3*, *KCNMA1*,
222 *KCNN1*, *OPRM1*) were implicated in opioid addiction, and all except the *GABRE* subunit were
223 associated with decreased expression or less active chromatin. Moreover, the EAAT2 glutamate
224 transporter (*SLCIA2*) was implicated by H3K27 hypoacetylation, an astrocytic transporter
225 responsible for removing glutamate from the synaptic cleft that has been implicated in bipolar
226 disorder and schizophrenia⁵⁴. Coupled with a net decrease in immediate early gene expression
227 (*ARC*, *EGR1*, *EGR2*, *EGR4*, *ETSI*, *ETV5*, *FOS*, *MYC*, *NPAS4*), genes whose expression is induced
228 by cellular activation⁵⁵⁻⁵⁹, our opioid addiction genes are associated with decreased neuronal
229 activity in the dlPFC. Future studies are warranted to determine if decreased gene expression and
230 H3K27 hypoacetylation occur equally within excitatory and inhibitory neurons in the dlPFC.

231 Extending GWAS findings for opioid addiction, here we integrated omics data in the dlPFC
232 based on its role in impulsivity and drug craving in opioid addiction³⁹⁻⁴¹. This brain region has
233 also been implicated in cigarette⁶⁰ and cocaine craving⁶¹. Moreover, randomized clinical trials
234 have been conducted using transcranial magnetic stimulation over this brain region to reduce
235 opioid craving^{62,63}. Although omics from whole blood^{53,64,65} and other brain regions, such as the
236 midbrain⁶⁶, nucleus accumbens^{13,67}, orbitofrontal cortex⁶⁸, and striatum^{69,70} have been generated
237 from individuals with a history of opioid addiction, focusing on GWAS and the dlPFC enabled us
238 to examine genes from a brain region-specific perspective. Future studies should examine
239 biological pathways involving NAc omics, particularly the extent to which these pathways overlap
240 with dlPFC pathways. Furthermore, while the H3K27ac ChIP-seq data set integrated in this study

241 were derived from NeuN-positive neurons¹¹, omics derived from other cell types (*e.g.*, astrocytes,
242 microglia, oligodendrocytes) and neuronal subtypes can inform cell type-specific epigenomic,
243 transcriptomic, and proteomic changes caused by opioid addiction.

244 After identifying opioid addiction genes in the dlPFC, we sought to identify which genes
245 were known targets of previously approved medications using network visualization. Notably,
246 approved treatments for opioid addiction⁷¹ (buprenorphine, methadone, naltrexone) or overdose
247 (nalmeferne and naloxone) were present within our drug-gene target network. In addition to these
248 opioid-related treatments, drugs for which there is evidence of efficacy in treating alcohol use
249 disorder were present in the network, including acamprosate²⁷, baclofen²⁷, ibudilast²⁸, and
250 topiramate. Of these, topiramate has limited evidence in clinical trials for its capacity to treat opioid
251 addiction⁷², and has been extensively assessed for treating alcohol use disorder²⁹ and to a lesser
252 extent cocaine⁷³ addiction. In addition to medications for treating substance use disorders, we
253 identified multiple drugs that are widely prescribed for treating psychiatric disorders that may be
254 comorbid with opioid addiction, such as depressive and anxiety disorders and schizophrenia.
255 Studies are warranted to evaluate the extent to which these drugs could be used to treat opioid
256 addiction. As many of the identified genes were associated with decreased gene expression or
257 hypoacetylated H3K72ac ChIP-seq peaks, ascertaining whether these drugs increase (agonist) or
258 decrease (antagonist) the downstream activity of these protein-coding genes is critical.
259 Furthermore, an important question for drug repurposing efforts is how opioid addiction affects
260 the expression of the genes identified in the dlPFC.

261 In considering drugs to be repurposed for treating addiction, weighing the potential risks
262 associated with them is essential. A number of drugs in the network that are widely used in
263 psychiatry, such as the benzodiazepines alprazolam³⁷ and lorazepam³⁸, have the potential for

264 misuse; thus, any efforts to repurpose these drugs must consider their potential for adverse effects.
265 Future work might also include using real world data to determine safety and whether there is
266 evidence that the use of these medications is associated with decreased use of opioids.

267 There are limitations to the current study that are worth noting. Notably, the omics from
268 the dlPFC included in the study are from bulk tissue, rather than individual cellular populations.
269 As they become available, integrating single-cell transcriptomic and epigenetic datasets would
270 give valuable insight into the neuronal and/or glial cell populations affected by opioid addiction in
271 the prefrontal cortex. Adding single cell-specific context into networks (*e.g.*, including a
272 glutamatergic neuron-specific predictive expression network) would provide additional cellular
273 perspective into the relationships among the multi-omic genes, beyond a tissue-level perspective.
274 Furthermore, gene dysregulation in the dlPFC was identified by comparing opioid overdose death
275 cases to controls. Such differences in gene regulation may be attributable to a variety of causes
276 (*e.g.*, chronic opioid exposure / addiction, genetic risks for opioid addiction, acute death from an
277 opioid overdose, differences in diet, other drug use, or circadian disruption). It is likely that
278 functional studies in model organisms will be needed to differentiate such causes. Finally, while
279 we have included currently available genes implicated by GWAS and omics data, there are likely
280 additional genes contributing to opioid addiction that have not yet been implicated due to these
281 genes failing to reach statistical significance. Thus, as sample sizes continue to increase from
282 opioid addiction GWAS and postmortem omics data from opioid overdose, there may be additional
283 genes and pathways implicated within the dlPFC based on increased statistical power.

284 In summary, we used network biology techniques to integrate multiple opioid addiction
285 omics data sets from a systems biology perspective. By identifying biological pathways
286 dysregulated in the dlPFC following opioid addiction and druggable gene targets in these

287 pathways, we identified candidate medications that merit experimental follow up as potential
288 treatments for opioid addiction.

289 **Online Methods**

290
291 *Integrating opioid addiction multi-omic genes.*

292 Opioid addiction genes were integrated from the following types of previously published
293 omics data sets involving postmortem dorsolateral prefrontal cortex (dlPFC) from control subjects
294 and subjects who died of an opioid overdose: H3K27ac chromatin immunoprecipitation
295 sequencing (ChIP-seq¹¹), DNA methylation¹⁵, liquid chromatography-mass spectrometry
296 (LC/MS¹²), and bulk RNA sequencing (RNA-seq¹¹⁻¹⁴). We also included genes identified from
297 opioid addiction genome-wide association studies (GWAS). Together, 404 unique genes present
298 in the multiplex network were identified based on the following thresholding procedures.

299 Differential ChIP-seq peaks were derived from previous H3K27ac ChIP-seq obtained from
300 prefrontal cortex samples of controls and subjects that died of opioid overdose (**Supplementary**
301 **Table 1**)¹¹. From 388 differentially acetylated H3K27ac ChIP-seq peaks based on a threshold of
302 Bonferroni-corrected $p < 1e^{-7}$, peaks were re-mapped to genes using the “annotatePeak” function
303 from the ChIPseeker R function⁷⁴ using hg19/GRCh37 coordinates and a 1kb window around the
304 transcriptional start site to define the promoter region. This annotation was used in contrast to the
305 GREAT⁷⁵ peak-to-gene annotation listed in the original publication¹¹, as ChIP-seeker annotates
306 the location of peaks (i.e. intronal, exonal, promoter, 5’UTR, 3’UTR, distal intergenic) and
307 mapped peaks to genes that GREAT did not annotate. Reciprocally, if ChIPseeker did not map a
308 peak to a gene, the GREAT peak-to-gene annotation was used. Together, these 388 H3K27ac
309 ChIP-seq peaks mapped to 267 unique genes. Furthermore, we included the 5 genes (*ASTN2*,

310 *DUSP4*, *ENOX1*, *GABBR2*, *KCNMA1*) associated with variant enhancer loci lost in opioid
311 overdose subjects using promoter-capture Hi-C that were statistically significant at FDR-corrected
312 $p < 1e^{-6}$, which added 2 unique genes to the H3K27ac ChIP-seq-associated gene list. Thirteen non-
313 coding RNAs identified by ChIP-seq peaks were excluded from downstream analysis as they were
314 not present in any layer of the multiplex network (**Supplementary Table 7**): *MIR30D*, *MIR3201*,
315 *MIR3914-1*, *MIR4262*, *MIR4264*, *MIR4319*, *MIR4432*, *MIR4480*, *MIR4689*, *MIR4714*, *MIR4790*,
316 *MIR488*, and *SNORA72*. In total, 256 unique genes were included among the H3K27ac ChIP-seq
317 peaks.

318 Differentially methylated genes were identified using a previously published epigenome-
319 wide association study of dlPFC tissue from subjects who died from opioid overdose using the
320 Illumina Infinium MethylationEPIC BeadChip DNA methylation chip testing 850,000 CpG
321 regions (**Supplementary Table 2**)¹⁵. Thirteen CpG sites were identified with adjusted p -values of
322 0.4 (uncorrected $p < 6e^{-6}$) and 3 CpG islands that were not mapped to genes (cg25084741,
323 cg10759972, and cg26506680) were excluded. This yielded 13 unique genes identified by opioid-
324 induced differential DNA methylation that were present in the multiplex network.

325 Genes were included from opioid use disorder⁸⁻¹⁰ and prescription opioid misuse⁶ GWAS
326 based on SNP-nearest gene associations from SNPs with $p < 5e^{-8}$, resulting in 19 unique GWAS
327 genes; an additional 15 unique genes were also identified from multi-trait analysis of GWAS
328 (MTAG) using European opioid use disorder GWAS, alcohol use disorder, and cannabis use
329 disorder summary statistics (**Supplementary Table 3**)⁷. These opioid addiction GWAS yielded
330 34 unique genes, but one gene (*TMX2-CTNND1*) was not present in any layer of the multiplex
331 and was excluded from downstream analyses (33 unique GWAS genes; **Supplementary Tables**
332 **6-7**).

333 Differentially abundant proteins (**Supplementary Table 4**) were identified from a
334 previously published LC/MS proteomics study from postmortem dlPFC from control and subjects
335 diagnosed with opioid use disorder¹². Three protein coding genes (*ATP5J2*, *LGALS3*, *TAF15*) were
336 included based on a threshold of adjusted p -value < 0.05 and absolute value of \log_2 fold change
337 (FC) greater than or equal to 1.5 ($\log_2\text{FC} \leq -1.5$ or $\log_2\text{FC} \geq 1.5$) which were included in
338 downstream analyses.

339 Differentially expressed genes (DEGs; **Supplementary Table 5**) were identified from four
340 RNA-seq studies derived from postmortem dlPFC of controls and subjects who died of opioid
341 overdose or were diagnosed with opioid use disorder¹¹⁻¹⁴. DEGs were included in downstream
342 analyses based on thresholds of adjusted p -value < 0.05 and $|\log_2\text{FC}| \geq 0.5$. Using these thresholds,
343 we identified 106 unique genes identified in opioid addiction by RNA-seq and 103 genes present
344 in the multiplex were included in downstream analyses (*AC018647.3*, *AL606753.2*, and *PARTICL*
345 were excluded, **Supplementary Table 7**).

346 Multiple genes were implicated in opioid addiction by multiple lines of biological
347 evidence. Four genes were identified across multiple omics data types: *DUSP4*, *DUSP6*, *ETV5*,
348 and *PLA2GS*. Additionally, 60 ChIP-seq opioid addiction genes were identified by multiple
349 H3K27ac ChIP-seq peaks, and *ARL4D* was identified as a DEG in two separate RNA-seq
350 studies^{12,13}. Furthermore, *FURIN*⁷⁻⁹, *NCAMI*^{7,8}, *OPRM1*⁷⁻¹⁰, and the *SCAI/PPP6C/RABEPK*⁷⁻⁹
351 gene cluster were identified across multiple opioid addiction GWAS.

352

353 *Multiplex network generation.*

354 Multiplex gene-gene networks were assembled from 10 layers from different types of
355 biological evidence using GENCODE IDs for all genes. None of the multiplex network data

356 sources were from any of the opioid addiction omics data sets. The following network layers were
357 used from HumanNet (version 2.0²³): co-citation, co-essentiality, co-expression, pathway
358 databases, gene neighborhood, interologs, and phylogenetic associations. A merged protein-
359 protein interaction network was created by merging networks from HumanNet (version 2.0,
360 literature curated and high-throughput assay-derived connections) and high-confidence
361 interactions from STRING (version 11.0, taxa = 9606, protein.actions.v11.0, mode=binding, min
362 score = 700⁷⁶). Transcription factor-target relationships specific to the prefrontal cortex were
363 included from Pearl et al²⁰. All edge (connection) weights were normalized on a 0 to 1 scale
364 irrespective of line of biological evidence.

365 Brain region-specific network layers were also incorporated using RNA-seq data from the
366 Genotype-Tissue Expression (GTEx) consortium⁷⁷ and explainable-AI algorithms applied on the
367 Summit supercomputer at the Oak Ridge Leadership Computing Facility (OLCF). Using iterative
368 random forest leave-one-out prediction (iRF-LOOP⁷⁸), gene-gene predictive networks were made
369 from the prefrontal cortex (BA9) given that all omics were derived from this brain region. After
370 computing all edges with iRF-LOOP, only high-confidence edges (edge weights > 0.05) were
371 included in the multiplex network.

372 After compiling all network layers, the 10-layer multiplex was assembled using the
373 “RWR_make_multiplex” function within the RWRtoolkit R library⁷⁹. The final multiplex network
374 contained 51,183 unique genes and 3,419,975 unique edges.

375

376 *Filtering opioid addiction multi-omic genes using GRIN*

377 We applied GRIN (Geneset Refinement using Interacting Networks)¹⁷ to identify the most
378 biologically interrelated opioid addiction genes and remove potential false positive genes. GRIN

379 was applied with the previously validated 10-layer multiplex network described above using the
380 404 unique genes identified from multiple omics data using equal weights for all genes. GRIN
381 retained 211 opioid addiction genes which were used in all subsequent analyses. Gene set
382 enrichment for Gene Ontology (GO) Biological Processes was then tested on the 404 genes prior
383 to GRIN as well as the GRIN retained and GRIN removed gene sets using ToppGene⁸⁰. Gene set
384 enrichments were considered significant at a threshold of FDR-corrected p -value < 0.05 .

385 After retaining 211 opioid addiction genes, a set of 50 high-confidence genes were
386 identified using two criteria. Three genes that were present in multiple omics data sets and retained
387 by GRIN were included: *DUSP4*, *DUSP6*, and *ETV5*. Next, a subset of the 211 genes was included
388 if each gene were associated with opioid-mediated signaling or a substance use disorder based on
389 previously published research. This resulted in 47 additional genes in the high-confidence gene set
390 based on a literature search from PubMed (<https://pubmed.gov>) using the following search terms:
391 “[gene] opioid”, “[gene] addiction”, “[gene] substance use disorder.” ToppGene was then used to
392 test for gene set enrichment of GO Biological Processes, GO Cellular Components, GO Molecular
393 Functions, biological pathway enrichment (includes KEGG⁸¹, Reactome⁸², and PANTHER⁸³
394 pathways), and transcription factor binding sites (MSigDB⁸⁴).

395

396 *Shortest paths network*

397 A shortest paths network connecting all pairs of the 50 opioid addiction-associated genes
398 was generated using the shortest paths algorithm using the R package RWRtoolkit⁷⁹. The 10-layer
399 multiplex network was merged into a single network layer, and using the shortest paths algorithm
400 identified the shortest possible network connections among all 2500 possible gene-gene pairs.
401 Genes who were direct neighbors with at least one other opioid addiction gene (43 out of 50 opioid

402 addiction genes) were imported into the program Cytoscape⁸⁵ (Version 3.9.1, Cytoscape
403 Consortium, San Diego, CA, USA) for network visualization. For the other 7 genes (*ADRAID*,
404 *FURIN*, *KIAA0040*, *LGALS3*, *NTN1*, *SLC1A2*, *SST*), the connections between these genes and
405 other opioid addiction genes that were separated by one neighbor (“network-connecting genes”)
406 were included in the Cytoscape visualization.

407

408 *Random walk with restart cross validation.*

409 Using the RWR-CV function within RWRtoolkit⁷⁹, we tested the interconnectivity of our
410 refined 50 opioid addiction gene set using random walk with restart (RWR) with 5-fold cross
411 validation. In one cross validation fold, 10 genes were left out of our input gene set, and the other
412 40 genes were used as seed genes for RWR. All genes in the multiplex network were ranked by
413 RWR, with true positives counted as left-out genes that were ranked by RWR, and true negatives
414 counted as other genes in the network. A receiver-operator characteristic (ROC) curve was
415 calculated based on true positive rate (true positives / true positives + false negatives) and false
416 positive rate (false positives / false positives + true negatives), which was plotted using the R
417 package ggplot2⁸⁶. The area under the curve was computed using RWRtoolkit.

418

419 *Overview and conceptual model visualizations*

420 An overview diagram of the approach used in this study was constructed using
421 Biorender.com. Similarly, the conceptual model illustrating biological pathways among opioid
422 addiction genes was constructed using Biorender.com.

423

424 *Identifying druggable targets involved in opioid addiction.*

425 Multi-omic opioid addiction genes were then cross-referenced with previously
426 demonstrated gene-drug interactions. Using DrugBank⁸⁷, a network of drug-gene target
427 interactions was created using all 211 genes retained by GRIN. These drug interactions included
428 FDA-approved, investigational, and experimental uses of drugs targeting these genes, resulting in
429 48 gene targets and 414 total drugs. Drug-gene target interactions were visualized using Cytoscape.

430 **Data Availability**

431 No primary data was generated for the present study. All primary data from DNA
432 methylation, GWAS summary statistics, H3K27ac ChIP-seq, LC/MS proteomics, and RNA-seq
433 are from previously published manuscripts. GWAS summary statistics from the Million Veteran
434 Program (Kember et al., 2022) are available on the NIH database of Genotypes and Phenotypes
435 (dbGaP) under accession phs001672. GWAS summary statistics from Deak et al., 2022 are
436 publicly available at <https://medicine.yale.edu/lab/gelernter/stats/>. GWAS summary statistics
437 from Gaddis et al., 2022 are available under dbGaP under accession phs000454.v1.p1. We used
438 the top 10,000 SNPs from Sanchez-Roige et al., 2021 GWAS summary statistics, which are
439 publicly available at
440 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8562028/bin/41380_2021_1335_MOESM2_ESM.xlsx. Previously published data from H3K27ac ChIP-seq is available under dbGaP accession
441 number phs002724.v1.p1. Previously published DNA methylation data is available at GEO
442 accession number GSE164822. Previously published LC/MS proteomics is available at the
443 ProteomeXchange PRIDE repository under PXD025269. Previously published RNA-seq data
444 sets are available under dbGaP accession phs002724.v1.p1, GEO accession numbers
445 GSE221515 and GSE174409, and SRA accession number SUB9455518.

447 All activities were approved by the Oak Ridge National Laboratory Institutional Review
448 Board. The demographics of subjects from which GWAS summary statistics were derived along
449 with descriptions of Institutional Review Boards to approve these studies have been
450 characterized in previous publications and all subjects provided informed consent. All
451 postmortem brain tissue samples are exempt from human subjects research.

452

453 **Code Availability**

454 The GRIN software and multiplex network that was used is publicly available at
455 github.com/sullivanka/GRIN. Publicly available R packages (ggplot2, tidyverse) were used for
456 data analysis and visualization using R version 4.1.3, and ChIP-seq peaks were assigned using
457 ChIPseeker (version 1.30.3). Additional code used to generate results are available upon request.

458 **Acknowledgements/Funding Sources**

459 This manuscript has been authored by UT-Battelle, LLC under Contract No. DE-AC05-
460 00OR22725 with the U.S. Department of Energy. The United States Government retains and the
461 publisher, by accepting the article for publication, acknowledges that the United States
462 Government retains a non-exclusive, paid-up, irrevocable, world-wide license to publish or
463 reproduce the published form of this manuscript, or allow others to do so, for United States
464 Government purposes. The Department of Energy will provide public access to these results of
465 federally sponsored research in accordance with the DOE Public Access Plan
466 (<http://energy.gov/downloads/doe-public-access-plan>). This research used resources of the Oak
467 Ridge Leadership Computing Facility, which is a DOE Office of Science User Facility supported

468 under Contract DE-AC05-00OR22725. This work was funded by NIH grants DA051908 (EOJ,
469 DAJ), DA051913 (DBH, DAJ), and DA054071 (NCG, OC, BSM, SS, AP, VT, EC, EOJ, DAJ)
470 and VA grant I01 BX004820 (ACJ, HRK) and the Veterans Integrated Service Network Mental
471 Illness Research, Education and Clinical Center (HRK). This research is based on data from the
472 Million Veteran Program, Office of Research and Development, Veterans Health Administration,
473 and was supported by award # I01 BX004820. This publication does not represent the views of
474 the Department of Veteran Affairs or the United States Government.

475

476 **Author Contributions**


477 Conceptualization: DBH, EOJ, DAJ; Methodology: KAS; Software: KAS, DK, ML, MC, JIM;
478 Formal analysis: KAS; Investigation: EOJ; Writing - Original Draft: KAS, EOJ; Writing - Review
479 & Editing: KAS, MRG, AT, BCQ, CW, NCG, RM, OC, BSM, PCS, SS, AP, VT, EJC, RLK,
480 HRK, ACJ, KX, BEA, DBH, EOJ, DAJ; Supervision: DBH, EOJ, DAJ; Funding acquisition:
481 HRK, ACJ, DBH, EOJ, DAJ.

482 **Competing Interests**

483 HRK is a member of advisory boards for Dicerna Pharmaceuticals, Sophrosyne Pharmaceuticals,
484 Enthion Pharmaceuticals, and Clearmind Medicine; a consultant to Sobrera Pharmaceuticals; the
485 recipient of research funding and medication supplies from Alkermes for an investigator-initiated
486 study; a member of the American Society of Clinical Psychopharmacology's Alcohol Clinical
487 Trials Initiative, which was supported in the last three years by Alkermes, Dicerna, Ethypharm,
488 Lundbeck, Mitsubishi, and Otsuka; and is named as an inventor on PCT patent application

489 #15/878,640 entitled: "Genotype-guided dosing of opioid agonists," filed January 24, 2018. The
490 other authors have no disclosures to make.


491 Figures



492

493 Figure 1. Multi-omic integration of opioid addiction phenotypes.



494 Beginning with multiple data sets collected from opioid addiction (OA) cases and controls, OA
495 genes were assembled from H3K27ac chromatin immunoprecipitation (ChIP-seq; peaks assigned
496 to nearest gene), DNA methylation (CpG methylation site to nearest gene), genome-wide
497 association studies (GWAS; SNP-to-gene assignment), differentially abundant proteins by LC/MS
498 proteomics (protein-coding genes), and differential gene expression by RNA-seq. After integrating
499 the overlapping and distinct genes identified by each omics data type, a biological multiplex
500 network consisting of networks from multiple lines of biological evidence were constructed using
501 data sources separate from any of the opioid addiction omics data sets. Network traversal
502 algorithms were used to identify mechanistic connections among the multi-omic genes and identify
503 dysregulated pathways in the dorsolateral prefrontal cortex (dlPFC). Figure made with
504 Biorender.com.



505

506 **Figure 2. Opioid addiction genes are retained by GRIN from multiple omics types**
 507 **and result in more Gene Ontology enrichments compared to the unfiltered gene set.**

508 **a.** Percentages of genes retained (orange) or removed (blue) by GRIN by each omics type,
 509 including genes shared across omics types (ChIP-seq_RNAseq, GWAS_MTAG_GWAS, pHiC-
 510 VELs_ChIPseq, and pHiC-VELs_ChIPseq_RNAseq). **b.** From the 404 original opioid addiction
 511 genes (Pre-GRIN), 159 GO Biological Process terms were significantly enriched. The 211 genes
 512 retained by GRIN (Post-GRIN) were enriched for 96 of the same GO Biological Processes but
 513 were uniquely enriched for 197 additional terms. Only 7 terms were significantly enriched in the
 514 set of 404 genes prior to GRIN that were not significantly enriched in the post-GRIN set of 211
 515 genes.




516

517 **Figure 3. Multi-omic opioid addiction genes are tightly interconnected as**
 518 **demonstrated by network biology.**

519 **a.** Network visualization of the shortest pathways between all pairs of 50 opioid addiction (OA)-
 520 associated genes from GWAS and dIPFC omics. 43 genes were directly connected to at least one
 521 other gene by the networks (Direct Neighbor OA genes), and only 127 additional genes (Network-
 522 Connecting Genes) were necessary to connect the other 7 genes (One Neighbor OA Genes) from
 523 10 network layers. Notably, three Network-Connecting genes (*SERPINB1*, *SORCS1*, and *SORL1*)


524 were members of the larger 211 GRIN-retained opioid addiction gene set. Gene Legend: indicates
525 gene color from which omics data type or if it is a Network-Connecting Gene; Network
526 Connections legend indicates network layer used to connect gene pairs. **b.** Using Random Walk
527 with Restart to explore the biological networks starting from 50 OA-associated genes, 5-fold cross
528 validation exhibits high recall based upon a mean area under receiver-operator characteristic curve
529 (AUROC) value of 0.94.



530

531 **Figure 4. Conceptual model of opioid addiction pathways implicated by multi-omic**
 532 **integration.**

533 Conceptual model of 45 opioid addiction genes identified via multiple omics data types and 26
 534 additional genes, proteins, or molecules in associated pathways. The mu-opioid receptor (*OPRM1*)
 535 and *GABBR2* receptor inhibit downstream adenylyl cyclase/protein kinase A (PKA) signaling.
 536 PKA can phosphorylate ERK1 which is bound by the scaffolding protein PEA-15, and ERK can
 537 also be activated by upstream netrin (*NTN1*) and BDNF signaling molecules that were implicated
 538 in opioid addiction (*BDNF*, *NTRK2*, *RASGRF1*). *DUSP2*, *DUSP4*, *DUSP6*, *DUSP10*, and *PPP6C*
 539 all function as ERK phosphatases and *PDE4B* can reduce PKA activation, while Akt signaling
 540 (implicated by *PIK3RA* and *GSK3B*) and ERK signaling can activate *NPAS4* and *CREB5* to
 541 activate transcription of *NTN1* (identified by DNA hypermethylation) and synaptic plasticity and
 542 immediate early genes (*ARC*, *BDNF*, *EGR1*, *EGR2*, *EGR4*, *ETS1*, *ETV5*, *FOS*, *MYC*, *NPAS4*, *SST*).
 543 ERK can also activate the transcription factor *RORA* to promote transcription of *ASTN2* and
 544 galectin-3 (*LGALS3*), which is important in microglial inflammatory processes. *OPRM1*
 545 (chaperoned to the cell membrane by *RTP4*) and *FURIN* share a common scaffolding protein
 546 (filamin A; *FLNA*) with the glutamatergic kainate receptor subunit *GRIK3*, and *SLC1A2* is an
 547 important glutamate transporter in astrocytes. Additional potassium and calcium channel subunits
 548 (*ABCC8*, *KCNMA1*, *KCNN1*) were implicated along with multiple ionotropic GABA_A receptor
 549 subunits (*GABRE*, *GABRG3*) and cell adhesion molecules (*NCAM1* and *NRXN3*). Color of gene
 550 text indicates which opioid addiction omics data set the gene originated from, and shading of the
 551 gene indicates the logFC of expression or histone acetylation state (not applicable for pc Hi-C
 552 VELS or GWAS genes). *NTN1* was hypermethylated by a mean difference of 0.29 rather than a
 553 logFC difference in methylation state. Gray text genes indicate genes or molecules involved in
 554 pathways but were not implicated by an omics study.



555 **Figure 5. Drug-gene target network includes current opioid treatments and putative**
 556 **candidate drugs for treatment repurposing.**

557 A network of 414 drugs and 48 target genes (orange) implicated in multi-omic opioid addiction
 558 studies. Current opioid addiction/opioid use disorder (OUD) treatments (light yellow-green)
 559 targeting the μ -opioid receptor (*OPRM1*) include buprenorphine, methadone, and naltrexone, as
 560 well as nalmefene and naloxone to prevent overdose. In addition to nalmefene and naltrexone
 561 which is used to treat OUD and alcohol use disorder (AUD), four approved or experimental alcohol
 562 use disorder treatments (light green) were present in the network: acamprosate (targeting *GABRE*
 563 and *GABRG3*), baclofen (targeting *GABBR2*), ibudilast (targeting *PDE4B*), and topiramate
 564 (*CACNB2*, *GRIK3*, and *SCN8A*). Drugs with known psychiatric effects (teal) targeting opioid
 565 addiction genes include spironolactone (also investigated for AUD), antidepressants (e.g.,
 566 amitriptyline, amoxipine, and esketamine, targeting 6 unique genes). Some drugs in the network
 567 with known misuse potential (dark blue) include antipsychotic drugs (e.g., aripiprazole,
 568 quetiapine) and many benzodiazepines that act as anxiolytics (e.g., alprazolam, lorazepam).
 569 Multiple ion channel receptor subunits (15 total) are also known drug targets, and 9 genes are
 570 known to be targeted by fostamatinib. Other drugs with yet unknown psychiatric effects targeting
 571 opioid addiction genes are shown in light blue, along with a number of opioids (gray). This drug-
 572 gene target network may guide additional hypotheses and follow up experiments to test the
 573 efficacy of these drugs in combating opioid addiction processes.

574 **References**

- 575 1. Unodc. World drug report 2021-drug market trends: cannabis & opioids. (2021).
- 576 2. Substance Abuse and Mental Health Services Administration. Key substance use and mental
577 health indicators in the United States: Results from the 2020 national survey on drug use and
578 health. (*HHS Publication No. PEP21-07-01-003, NSDUH Series H-56*). (2021).
- 579 3. Spencer, M., Miniño, A. & Warner, M. *Drug overdose deaths in the United States, 2001–*
580 *2021*. <https://stacks.cdc.gov/view/cdc/122556> (2022) doi:10.15620/cdc:122556.
- 581 4. Ahmad FB, Cisewski JA, Rossen LM, Sutton P. Provisional drug overdose death counts.
582 *National Center for Health Statistics*. (2023).
- 583 5. U.S. Department of Health and Human Services. HHS By The Numbers: Combating the
584 Opioids Crisis. (2019).
- 585 6. Sanchez-Roige, S. *et al.* Genome-wide association study of problematic opioid prescription
586 use in 132,113 23andMe research participants of European ancestry. *Mol. Psychiatry* **26**,
587 6209–6217 (2021).
- 588 7. Deak, J. D. *et al.* Genome-wide association study in individuals of European and African
589 ancestry and multi-trait analysis of opioid use disorder identifies 19 independent genome-
590 wide significant risk loci. *Mol. Psychiatry* (2022) doi:10.1038/s41380-022-01709-1.
- 591 8. Kember, R. L. *et al.* Cross-ancestry meta-analysis of opioid use disorder uncovers novel loci
592 with predominant effects in brain regions associated with addiction. *Nat. Neurosci.* (2022)
593 doi:10.1038/s41593-022-01160-z.
- 594 9. Gaddis, N. *et al.* Multi-trait genome-wide association study of opioid addiction: OPRM1
595 and beyond. *Sci. Rep.* **12**, 16873 (2022).
- 596 10. Zhou, H. *et al.* Association of OPRM1 Functional Coding Variant with Opioid Use
597 Disorder: A Genome-Wide Association Study. *JAMA Psychiatry* **77**, 1072–1080 (2020).

- 598 11. Corradin, O. *et al.* Convergence of case-specific epigenetic alterations identify a confluence
599 of genetic vulnerabilities tied to opioid overdose. *Mol. Psychiatry* **27**, 2158–2170 (2022).
- 600 12. Mendez, E. F. *et al.* Angiogenic gene networks are dysregulated in opioid use disorder:
601 evidence from multi-omics and imaging of postmortem human brain. *Mol. Psychiatry*
602 (2021) doi:10.1038/s41380-021-01259-y.
- 603 13. Seney, M. L. *et al.* Transcriptional Alterations in Dorsolateral Prefrontal Cortex and Nucleus
604 Accumbens Implicate Neuroinflammation and Synaptic Remodeling in Opioid Use
605 Disorder. *Biol. Psychiatry* **90**, 550–562 (2021).
- 606 14. Sosnowski, D. W. *et al.* Differential expression of NPAS4 in the dorsolateral prefrontal
607 cortex following opioid overdose. *Drug and Alcohol Dependence Reports* **3**, 100040 (2022).
- 608 15. Shu, C. *et al.* Epigenome-wide study of brain DNA methylation following acute opioid
609 intoxication. *Drug Alcohol Depend.* **221**, 1–7 (2021).
- 610 16. Carter, J. Quach, B., Willis, C., Hancock, D., Montalvo-Ortiz, J., Logan, R., Walss-Bass, C.,
611 Maher, B., Johnson, E., PGC-SUD Epigenetics Working Group. Identifying novel gene
612 dysregulation associated with opioid overdose death: A meta-analysis of differential gene
613 expression in human prefrontal cortex; Poster Presentation: PB1478. American Society of
614 Human Genetics, Los Angeles, CA, Oct 2022.
- 615 17. Sullivan, K. A. *et al.* Digging deeper into GWAS signal using GRIN implicates additional
616 genes contributing to suicidal behavior. *bioRxiv* (2022) doi:10.1101/2022.04.20.22273895.
- 617 18. Harris, M. A. *et al.* The Gene Ontology (GO) database and informatics resource. *Nucleic*
618 *Acids Res.* **32**, D258–61 (2004).
- 619 19. Funahashi, Y. *et al.* Phosphorylation of Npas4 by MAPK Regulates Reward-Related Gene
620 Expression and Behaviors. *Cell Rep.* **29**, 3235–3252.e9 (2019).

- 621 20. Pearl, J. R. *et al.* Genome-Scale Transcriptional Regulatory Network Models of Psychiatric
622 and Neurodegenerative Disorders. *Cell Systems* **8**, 122–135.e7 (2019).
- 623 21. Onoprishvili, I. *et al.* Interaction between the mu opioid receptor and filamin A is involved
624 in receptor regulation and trafficking. *Mol. Pharmacol.* **64**, 1092–1100 (2003).
- 625 22. Liu, G. *et al.* Cytoskeletal protein ABP-280 directs the intracellular trafficking of furin and
626 modulates proprotein processing in the endocytic pathway. *J. Cell Biol.* **139**, 1719–1733
627 (1997).
- 628 23. Hwang, S. *et al.* HumanNet v2: human gene networks for disease research. *Nucleic Acids*
629 *Res.* **47**, D573–D580 (2019).
- 630 24. Schachner, M. Neural recognition molecules and synaptic plasticity. *Curr. Opin. Cell Biol.*
631 **9**, 627–634 (1997).
- 632 25. Dai, J., Liakath-Ali, K., Golf, S. R. & Südhof, T. C. Distinct neurexin-cerebellin complexes
633 control AMPA- and NMDA-receptor responses in a circuit-dependent manner. *Elife* **11**,
634 (2022).
- 635 26. Liu, Y. *et al.* Galectin-3 regulates microglial activation and promotes inflammation through
636 TLR4/MyD88/NF- κ B in experimental autoimmune uveitis. *Clin. Immunol.* **236**, 108939
637 (2022).
- 638 27. Carpenter, J. E., LaPrad, D., Dayo, Y., DeGrote, S. & Williamson, K. An Overview of
639 Pharmacotherapy Options for Alcohol Use Disorder. *Fed. Pract.* **35**, 48–58 (2018).
- 640 28. Grodin, E. N. *et al.* Ibudilast, a neuroimmune modulator, reduces heavy drinking and
641 alcohol cue-elicited neural activation: a randomized trial. *Transl. Psychiatry* **11**, 355 (2021).
- 642 29. Kranzler, H. R. *et al.* Post-treatment effects of topiramate on alcohol-related outcomes: A
643 combined analysis of two placebo-controlled trials. *Addict. Biol.* **27**, e13130 (2022).

- 644 30. Farokhnia, M. *et al.* Spironolactone as a potential new pharmacotherapy for alcohol use
645 disorder: convergent evidence from rodent and human studies. *Mol. Psychiatry* **27**, 4642–
646 4652 (2022).
- 647 31. Jha, M. K. *et al.* Intranasal esketamine effectively treats treatment-resistant depression in
648 adults regardless of baseline irritability. *J. Affect. Disord.* **321**, 153–160 (2023).
- 649 32. Kishi, T. *et al.* Antidepressants for the treatment of adults with major depressive disorder in
650 the maintenance phase: a systematic review and network meta-analysis. *Mol. Psychiatry*
651 (2022) doi:10.1038/s41380-022-01824-z.
- 652 33. Merino, D. *et al.* Antipsychotic Abuse, Dependence, and Withdrawal in the Pediatric
653 Population: A Real-World Disproportionality Analysis. *Biomedicines* **10**, (2022).
- 654 34. Ferreira, R. C. M. *et al.* Peripheral Antinociception Induced by Aripiprazole Is Mediated by
655 the Opioid System. *Biomed Res. Int.* **2017**, 8109205 (2017).
- 656 35. Dorman, A., Talbot, D., Byrne, P. & O'Connor, J. Misuse of dothiepin. *BMJ* **311**, 1502
657 (1995).
- 658 36. Klein, L., Bangh, S. & Cole, J. B. Intentional Recreational Abuse of Quetiapine Compared
659 to Other Second-generation Antipsychotics. *West. J. Emerg. Med.* **18**, 243–250 (2017).
- 660 37. Ait-Daoud, N., Hamby, A. S., Sharma, S. & Blevins, D. A Review of Alprazolam Use,
661 Misuse, and Withdrawal. *J. Addict. Med.* **12**, 4–10 (2018).
- 662 38. Garretty, D. J., Wolff, K., Hay, A. W. & Raistrick, D. Benzodiazepine misuse by drug
663 addicts. *Ann. Clin. Biochem.* **34 (Pt 1)**, 68–73 (1997).
- 664 39. Liu, S. *et al.* Brain responses to drug cues predict craving changes in abstinent heroin users:
665 A preliminary study. *Neuroimage* **237**, 118169 (2021).
- 666 40. Wang, L. *et al.* Altered brain intrinsic functional hubs and connectivity associated with

- 667 relapse risk in heroin dependents undergoing methadone maintenance treatment: A resting-
668 state fMRI study. *Drug Alcohol Depend.* **219**, 108503 (2021).
- 669 41. Huhn, A. S. *et al.* Prefrontal cortex response to drug cues, craving, and current depressive
670 symptoms are associated with treatment outcomes in methadone-maintained patients.
671 *Neuropsychopharmacology* **44**, 826–833 (2019).
- 672 42. Doherty, J. M., Cooke, B. M. & Frantz, K. J. A role for the prefrontal cortex in heroin-
673 seeking after forced abstinence by adult male rats but not adolescents.
674 *Neuropsychopharmacology* **38**, 446–454 (2013).
- 675 43. Kuntz, K. L., Patel, K. M., Grigson, P. S., Freeman, W. M. & Vrana, K. E. Heroin self-
676 administration: II. CNS gene expression following withdrawal and cue-induced drug-
677 seeking behavior. *Pharmacol. Biochem. Behav.* **90**, 349–356 (2008).
- 678 44. Koya, E. *et al.* Enhanced cortical and accumbal molecular reactivity associated with
679 conditioned heroin, but not sucrose-seeking behaviour. *J. Neurochem.* **98**, 905–915 (2006).
- 680 45. Flaisher-Grinberg, S., Persaud, S. D., Loh, H. H. & Wei, L.-N. Stress-induced epigenetic
681 regulation of κ -opioid receptor gene involves transcription factor c-Myc. *Proc. Natl. Acad.*
682 *Sci. U. S. A.* **109**, 9167–9172 (2012).
- 683 46. Park, S. W., Li, J., Loh, H. H. & Wei, L.-N. A novel signaling pathway of nitric oxide on
684 transcriptional regulation of mouse kappa opioid receptor gene. *J. Neurosci.* **22**, 7941–7947
685 (2002).
- 686 47. Tsai, N.-P., Bi, J., Loh, H. H. & Wei, L.-N. Netrin-1 signaling regulates de novo protein
687 synthesis of kappa opioid receptor by facilitating polysomal partition of its mRNA. *J.*
688 *Neurosci.* **26**, 9743–9749 (2006).
- 689 48. Décaillot, F. M., Rozenfeld, R., Gupta, A. & Devi, L. A. Cell surface targeting of mu-delta

- 690 opioid receptor heterodimers by RTP4. *Proc. Natl. Acad. Sci. U. S. A.* **105**, 16045–16050
691 (2008).
- 692 49. Fujita, W. *et al.* Regulation of an Opioid Receptor Chaperone Protein, RTP4, by Morphine.
693 *Mol. Pharmacol.* **95**, 11–19 (2019).
- 694 50. Bagherpasand, N. *et al.* Effect of topiramate on morphine-induced conditioned place
695 preference (Cp) in rats: Role of erk and creb proteins in hippocampus and cerebral cortex.
696 *Iranian Journal of Pharmaceutical Research* **18**, 2000–2010 (2019).
- 697 51. Ramos-Miguel, A., Esteban, S. & García-Sevilla, J. A. The time course of unconditioned
698 morphine-induced psychomotor sensitization mirrors the phosphorylation of FADD and
699 MEK/ERK in rat striatum: role of PEA-15 as a FADD-ERK binding partner in striatal
700 plasticity. *Eur. Neuropsychopharmacol.* **20**, 49–64 (2010).
- 701 52. Koo, J. W. *et al.* Epigenetic basis of opiate suppression of Bdnf gene expression in the
702 ventral tegmental area. *Nat. Neurosci.* **18**, 415–422 (2015).
- 703 53. Dai, Q. *et al.* Whole Transcriptome Sequencing of Peripheral Blood Shows That
704 Immunity/GnRH/PI3K-Akt Pathways Are Associated With Opioid Use Disorder. *Front.*
705 *Psychiatry* **13**, 893303 (2022).
- 706 54. Fiorentino, A., Sharp, S. I. & McQuillin, A. Association of rare variation in the glutamate
707 receptor gene SLC1A2 with susceptibility to bipolar disorder and schizophrenia. *Eur. J.*
708 *Hum. Genet.* **23**, 1200–1206 (2015).
- 709 55. O’Donnell, A., Odrowaz, Z. & Sharrocks, A. D. Immediate-early gene activation by the
710 MAPK pathways: what do and don’t we know? *Biochem. Soc. Trans.* **40**, 58–66 (2012).
- 711 56. Heroux, N. A. *et al.* Differential expression of the immediate early genes c-Fos, Arc, Egr-1,
712 and Npas4 during long-term memory formation in the context preexposure facilitation effect

- 713 (CPFE). *Neurobiol. Learn. Mem.* **147**, 128–138 (2018).
- 714 57. Gerhauser, I., Alldinger, S., Ulrich, R. & Baumgärtner, W. Spatio-temporal expression of
715 immediate early genes in the central nervous system of SJL/J mice. *Int. J. Dev. Neurosci.*
716 **23**, 637–649 (2005).
- 717 58. Tran, D. D. H. *et al.* Transcriptional regulation of immediate-early gene response by
718 THOC5, a member of mRNA export complex, contributes to the M-CSF-induced
719 macrophage differentiation. *Cell Death Dis.* **4**, e879–e879 (2013).
- 720 59. Gao, P., Limpens, J. H. W., Spijker, S., Vanderschuren, L. J. M. J. & Voorn, P. Stable
721 immediate early gene expression patterns in medial prefrontal cortex and striatum after long-
722 term cocaine self-administration. *Addict. Biol.* **22**, 354–368 (2017).
- 723 60. Hayashi, T., Ko, J. H., Strafella, A. P. & Dagher, A. Dorsolateral prefrontal and
724 orbitofrontal cortex interactions during self-control of cigarette craving. *Proc. Natl. Acad.*
725 *Sci. U. S. A.* **110**, 4422–4427 (2013).
- 726 61. Huhn, A. S. *et al.* Increased neural activity in the right dorsolateral prefrontal cortex during
727 a risky decision-making task is associated with cocaine use in methadone-maintained
728 patients. *Drug Alcohol Depend.* **205**, 107650 (2019).
- 729 62. Eskandari, Z. *et al.* A sham-controlled clinical trial to examine the effect of bilateral tDCS
730 on craving, TNF- α and IL-6 expression levels, and impulsivity of males with opioid use
731 disorder. *J. Addict. Dis.* **39**, 347–356 (2021).
- 732 63. Tsai, T.-Y. *et al.* Add-on repetitive transcranial magnetic stimulation in patients with opioid
733 use disorder undergoing methadone maintenance therapy. *Am. J. Drug Alcohol Abuse* **47**,
734 330–343 (2021).
- 735 64. Cabrera-Mendoza, B. *et al.* Within subject cross-tissue analyzes of epigenetic clocks in

- 736 substance use disorder postmortem brain and blood. *Am. J. Med. Genet. B Neuropsychiatr.*
737 *Genet.* (2022) doi:10.1002/ajmg.b.32920.
- 738 65. Montalvo-Ortiz, J. L., Cheng, Z., Kranzler, H. R., Zhang, H. & Gelernter, J. Genomewide
739 Study of Epigenetic Biomarkers of Opioid Dependence in European- American Women.
740 *Sci. Rep.* **9**, 4660 (2019).
- 741 66. Saad, M. H. *et al.* Differentially expressed gene networks, biomarkers, long noncoding
742 RNAs, and shared responses with cocaine identified in the midbrains of human opioid
743 abusers. *Sci. Rep.* **9**, 1534 (2019).
- 744 67. Albertson, D. N., Schmidt, C. J., Kapatos, G. & Bannon, M. J. Distinctive profiles of gene
745 expression in the human nucleus accumbens associated with cocaine and heroin abuse.
746 *Neuropsychopharmacology* **31**, 2304–2312 (2006).
- 747 68. Kozlenkov, A. *et al.* DNA Methylation Profiling of Human Prefrontal Cortex Neurons in
748 Heroin Users Shows Significant Difference between Genomic Contexts of Hyper- and
749 Hypomethylation and a Younger Epigenetic Age. *Genes* **8**, (2017).
- 750 69. Egervari, G. *et al.* Chromatin accessibility mapping of the striatum identifies tyrosine kinase
751 FYN as a therapeutic target for heroin use disorder. *Nat. Commun.* **11**, 4634 (2020).
- 752 70. Egervari, G. *et al.* Striatal H3K27 Acetylation Linked to Glutamatergic Gene Dysregulation
753 in Human Heroin Abusers Holds Promise as Therapeutic Target. *Biol. Psychiatry* **81**, 585–
754 594 (2017).
- 755 71. Coffa, D. & Snyder, H. Opioid Use Disorder: Medical Treatment Options. *Am. Fam.*
756 *Physician* **100**, 416–425 (2019).
- 757 72. Zullino, D. F. *et al.* Topiramate in opiate withdrawal- comparison with clonidine and with
758 carbamazepine/mianserin. *Subst. Abus.* **25**, 27–33 (2004).

- 759 73. Rush, C. R. *et al.* Topiramate-phentermine combinations reduce cocaine self-administration
760 in humans. *Drug Alcohol Depend.* **218**, 108413 (2021).
- 761 74. Yu, G., Wang, L.-G. & He, Q.-Y. ChIPseeker: an R/Bioconductor package for ChIP peak
762 annotation, comparison and visualization. *Bioinformatics* **31**, 2382–2383 (2015).
- 763 75. McLean, C. Y. *et al.* GREAT improves functional interpretation of cis-regulatory regions.
764 *Nat. Biotechnol.* **28**, 495–501 (2010).
- 765 76. Szklarczyk, D. *et al.* STRING v11: protein-protein association networks with increased
766 coverage, supporting functional discovery in genome-wide experimental datasets. *Nucleic
767 Acids Res.* **47**, D607–D613 (2019).
- 768 77. Melé, M. *et al.* The human transcriptome across tissues and individuals. *Science* **348**, 660–
769 665 (2015).
- 770 78. Cliff, A. *et al.* A High-Performance Computing Implementation of Iterative Random Forest
771 for the Creation of Predictive Expression Networks. *Genes* **10**, (2019).
- 772 79. Kainer, D., Lane, M., Sullivan, K., Cashman, M. & Miller, J. *dkainer/RWRtoolkit*. (Oak
773 Ridge National Laboratory (ORNL), Oak Ridge, TN (United States), 2022).
774 doi:10.11578/DC.20220607.1.
- 775 80. Chen, J., Bardes, E. E., Aronow, B. J. & Jegga, A. G. ToppGene Suite for gene list
776 enrichment analysis and candidate gene prioritization. *Nucleic Acids Res.* **37**, W305–11
777 (2009).
- 778 81. Ogata, H., Goto, S., Fujibuchi, W. & Kanehisa, M. Computation with the KEGG pathway
779 database. *Biosystems.* **47**, 119–128 (1998).
- 780 82. Gillespie, M. *et al.* The reactome pathway knowledgebase 2022. *Nucleic Acids Res.* **50**,
781 D687–D692 (2022).

- 782 83. Mi, H. & Thomas, P. PANTHER pathway: an ontology-based pathway database coupled
783 with data analysis tools. *Methods Mol. Biol.* **563**, 123–140 (2009).
- 784 84. Liberzon, A. *et al.* Molecular signatures database (MSigDB) 3.0. *Bioinformatics* **27**, 1739–
785 1740 (2011).
- 786 85. Shannon, P. *et al.* Cytoscape: a software environment for integrated models of biomolecular
787 interaction networks. *Genome Res.* **13**, 2498–2504 (2003).
- 788 86. Wickham, H. *ggplot2: elegant graphics for data analysis* Springer-Verlag New York; 2009.
789 Preprint at (2016).
- 790 87. Wishart, D. S. *et al.* DrugBank 5.0: a major update to the DrugBank database for 2018.
791 *Nucleic Acids Res.* **46**, D1074–D1082 (2018).